Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 1
1996 2
1997 1
1998 2
1999 1
2003 4
2004 3
2005 1
2006 5
2007 3
2008 5
2009 3
2010 3
2011 10
2012 7
2013 6
2014 6
2015 6
2016 8
2017 12
2018 9
2019 12
2020 7
2021 7
2022 4
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladrón de Guevara Cetina AL, Janczewska E, Zigmond E, Jeong SH, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londoño Hurtado MC, Bergheanu S, Yang K, Choi YJ, Crittenden DB, McWherter CA; RESPONSE Study Group. Hirschfield GM, et al. Among authors: buggisch p. N Engl J Med. 2024 Feb 29;390(9):783-794. doi: 10.1056/NEJMoa2312100. Epub 2024 Feb 21. N Engl J Med. 2024. PMID: 38381664 Clinical Trial.
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F, Stein K, Heyne R, Petersen J, Buggisch P, Berg C, Zeuzem S, Stallmach A, Sprinzl M, Schott E, Pathil-Warth A, von Arnim U, Keitel V, Lohmeyer J, Simon KG, Trautwein C, Trein A, Hüppe D, Cornberg M, Lammert F, Ingiliz P, Zachoval R, Hinrichsen H, Zipprich A, Klinker H, Schulze Zur Wiesch J, Schmiedeknecht A, Brosteanu O, Berg T. van Bömmel F, et al. Among authors: buggisch p. J Hepatol. 2023 May;78(5):926-936. doi: 10.1016/j.jhep.2022.12.018. Epub 2023 Mar 28. J Hepatol. 2023. PMID: 37062574 Free article. Clinical Trial.
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
Dietz-Fricke C, Tacke F, Zöllner C, Demir M, Schmidt HH, Schramm C, Willuweit K, Lange CM, Weber S, Denk G, Berg CP, Grottenthaler JM, Merle U, Olkus A, Zeuzem S, Sprinzl K, Berg T, van Bömmel F, Wiegand J, Herta T, Seufferlein T, Zizer E, Dikopoulos N, Thimme R, Neumann-Haefelin C, Galle PR, Sprinzl M, Lohse AW, Schulze Zur Wiesch J, Kempski J, Geier A, Reiter FP, Schlevogt B, Gödiker J, Hofmann WP, Buggisch P, Kahlhöfer J, Port K, Maasoumy B, Cornberg M, Wedemeyer H, Deterding K. Dietz-Fricke C, et al. Among authors: buggisch p. JHEP Rep. 2023 Mar 15;5(4):100686. doi: 10.1016/j.jhepr.2023.100686. eCollection 2023 Apr. JHEP Rep. 2023. PMID: 37025462 Free PMC article.
[Strategietreffen: Virushepatitis in Deutschland eliminieren].
Tergast TL, Protzer U, Zeuzem S, Heitmann L, Sarrazin C, Lehmann M, Ingiliz P, Cornberg M, Zimmermann R, Gerlich MG, Buggisch P, Wiebner B, Wedemeyer H. Tergast TL, et al. Among authors: buggisch p. Z Gastroenterol. 2023 Feb;61(2):198-201. doi: 10.1055/a-1978-9021. Epub 2023 Feb 3. Z Gastroenterol. 2023. PMID: 36736343 Free PMC article. German. No abstract available.
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Dietz J, et al. Among authors: buggisch p. J Hepatol. 2023 Jan;78(1):57-66. doi: 10.1016/j.jhep.2022.08.016. Epub 2022 Aug 27. J Hepatol. 2023. PMID: 36031158
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions.
Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, Larrey D, Nikitin I, Pol S, Puoti M, Romero-Gómez M, Wedemeyer H, Zeuzem S. Burger D, et al. Among authors: buggisch p. J Hepatol. 2013 Apr;58(4):792-800. doi: 10.1016/j.jhep.2012.10.027. Epub 2012 Nov 5. J Hepatol. 2013. PMID: 23137766 Free article. Review.
Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-Registry.
Geier A, Rau M, Pathil-Warth A, von der Ohe M, Schattenberg J, Dikopoulos N, Stein K, Serfert Y, Berg T, Buggisch P, Demir M, Roeb E, Wiebner B, Wedemeyer H, Zeuzem S, Hofmann WP. Geier A, et al. Among authors: buggisch p. Z Gastroenterol. 2023 Jan;61(1):60-70. doi: 10.1055/a-1986-7676. Epub 2023 Jan 9. Z Gastroenterol. 2023. PMID: 36623544 English.
Management of hepatic encephalopathy in Germany: a survey among physicians.
Labenz C, Adarkwah CC, Wörns MA, Miehlke S, Hofmann WP, Buggisch P, Galle PR, Frieling T, Labenz J. Labenz C, et al. Among authors: buggisch p. Z Gastroenterol. 2020 Jan;58(1):49-56. doi: 10.1055/a-1010-6974. Epub 2020 Jan 13. Z Gastroenterol. 2020. PMID: 31931540 English.
121 results